Manufacturing roundup: AstraZeneca and Samsung ink $350M deal; Michigan CDMO completes expansion
Samsung’s biotech arm and AstraZeneca are looking to work together on a contract manufacturing agreement.
According to a report from Korea’s Yonhap News Agency, Samsung Biologics has signed a letter of intent with AstraZeneca on a cooperation deal valued at an estimated $350 million, but no other details on the deal were available.
Samsung Biologics told Yonhap that the companies exchanged a separate letter of intent last year to collaborate on biopharmaceutical manufacturing, but now the collaboration has grown due to increased demand from AstraZeneca.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.